PERCUTANEOUS MANAGEMENT OF MITRAL REGURGITATION

Slides:



Advertisements
Similar presentations
Natale MARRAZZO Francesco SOLIMENE Quando la CRT-P può bastare?
Advertisements

Percutaneous Therapy of Pulmonic and Mitral Valve Disease Atman P. Shah MD FACC FSCAI Director, Coronary Care Unit Assistant Professor of Medicine The.
Widimsky P, Tousek P, Rokyta R, et al. Charles University Prague, CZ PRAGUE-7 Study (Hot Lines presenter)
Percutaneous mitral valve repair using the MitraClip® device (e-valve)
ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.
Preliminary results from the C-Pulse OPTIONS HF European Multicenter Post-Market Study Holger Hotz, CardioCentrum Berlin, Berlin, Germany; Antonia Schulz,
ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW
INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc
STICH Mitral Regurgitation Subanalysis Objective Examine the relationship of mitral regurgitation (MR) severity and survival and compare outcomes in patients.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
New guidelines for CABG
Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation Right Ventricular Function and Pulmonary Artery Hypertension After Degenerative.
A shifting paradigm of care: Advances in transcatheter heart valve procedures Sandra Lauck MSN, RN, CCN(C) Clinical Nurse Specialist, Arrhythmia Management.
©2015 MFMER | Robotic Repair of Simple vs. Complex Degenerative Mitral Valve Disease Clinical and Echocardiographic Outcomes During Mid-Term.
Department of Surgery, University of Pennsylvania Health System Which Operation is Best for Severe Ischemic MR: Repair or Replace? Michael Acker William.
Randomized Trial of Ea rly S urgery Versus Conventional Treatment for Infective E ndocarditis (EASE) Duk-Hyun Kang, MD, PhD on behalf of The EASE Trial.
Valve Surgery V.Rohn. Valve Surgery History before the era of ECC 1925 – Suttar – first successful digital commisurolysis of mitral valve 1952 – Hufnagel.
MitraClip Mitral Valve Repair System Rachel McAteer BME 181.
Adult Cardiac Valve Disease Marvin D. Peyton, M.D. Thoracic and Cardiovascular Surgery University of Oklahoma Health Sciences Center.
EVEREST II Study Design Multicenter Randomized in a 2:1 ratio to either percutaneous or conventional surgery for the repair or replacement of the mitral.
+ Mitral Valve Prolapse A Surgeon’s Perspective Charles Anderson, M.D. Saint Joseph’s Hospital of Atlanta.
MITRAL RECONSTRUCTIVE SURGERY DEPARTMENT OF CARDIOTHORACIC SURGERY HOSPITAL DE SANTA MARIA LISBOA PORTUGAL.
MitraClip Mitral Valve Repair System Abbott Vascular MitraClip Mitral Valve Repair System Abbott Vascular Alexandra Camesas & Nathan Kukowski Biomaterials.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Cardiovascular Surgery J Am Coll Cardiol.
IN THE NAME OF GOD. What are Stem Cells? Stem cells are a class of undifferentiated cells that are able to differentiate into specialized cell types.
Date of download: 7/2/2016 Copyright © The American College of Cardiology. All rights reserved. From: Treatment of Chronic Functional Mitral Valve Regurgitation.
EXPANDING INDICATIONS OF TRANSCATHETER HEART VALVE INTERVENTIONS. JACC CARDIOVASCULAR INTERVENTION. DR.RAJAT GANDHI.
Primary Mitral Regurgitation Degenerative Mitral Valve Disease
© free-ppt-templates.com 2017 AHA/ACC Focused Update of Valvular Heart Disease Guideline of 2014 DR. OMAR SHAHID TR CARDIOLOGY SZH.
Current Surgical Standards for Mitral Leaflet and Chordal Repair: Patient Selection,Techniques and Clinical Outcomes CRT February 2011 Niv Ad, MD Chief,
Device Navigation Leaflet Capture Distal tip Saddle CAUTION: Investigational Device Limited by Federal (United States) Law to Investigational Use.
Role of Device Therapy in FMR: Challenges and Opportunities
From Mitral Repair to Replacement
CTSN Trials of Mitral Valve Repair and Replacement
Percutaneous treatment for Mitral Regurgitation
on behalf of the EVEREST Investigators
Cardiovacular Research Technologies
Management of mitral regurgitation. See legend for Fig
Mitral Regurgitation: Epidemiology, Pathophysiology and When to Repair
Cardiothoracic Surgery
Division of Cardiac Surgery University of Ottawa Heart Institute
University of Pennsylvania Philadelphia
Functional MR: When to Intervene
Mitralign Program Update
Transcatheter or Surgical Aortic Valve Replacement in Intermediate Risk Patients with Aortic Stenosis Description: The goal of the trial was to assess.
The CARILLON: Device Iteration, New Data and New Trials
Revascularization in Patients With Left Ventricular Dysfunction:
The Spectrum of Evolving Mitral Repair Techniques
TAVI Passed the Exam and is Ready for Clinical Use in Inoperable Patients Disclosures Research Funding and Speaking Honoraria: Edwards Lifesciences.
MITRALIGN: Direct Annuloplasty
How I treat Functional Mitral Regurgitation: The Surgeon’s perspective
Technology Update and Status of Current Clinical Trials
Opportunities to Study Valve Iterations and Modifications in the US
EVEREST II 5-Year Report and Beyond
Axel Linke University of Leipzig Heart Center, Leipzig, Germany
UNCERTAINTY OF RISK: THE CASE OF THE TRICUSPID DEVICES
Transcatheter Mitral Valve Repair Tips and tricks for access
James Hermiller, MD, FACC, FSCAI St Vincent Hospital, Indianapolis, IN
Niv Ad, MD Chief, Cardiac Surgery Inova Heart and Vascular Institute
S.G. Worthley, MB, BS, PhD., S. Redwood, MD, PhD.,
Risk Stratification of Severe, Symptomatic Aortic Stenosis Patients
Cardiovacular Research Technologies
Nishith Patel Waikato Cardiothoracic Unit
Ischemic Mitral Regurgitation
Samir R. Kapadia, MD On behalf of The PARTNER Trial Investigators
INOVATE-HF Trial design: Patients with heart failure (HF) were randomized to device implant for vagus nerve stimulation (n = 436) versus optimal medical.
Impact of Failed Mitral Clipping on Subsequent Mitral Valve Operations
Atlantic Cardiovascular Patient Outcomes Research Team
Transcatheter versus medical treatment of symptomatic severe tricuspid regurgitation: a propensity score matched analysis Maurizio Taramasso MD, PhD from.
Presentation transcript:

PERCUTANEOUS MANAGEMENT OF MITRAL REGURGITATION DR. HIMAL RAJ. M

INTRODUCTION Severe mitral regurgitation - insidious disorder Medical therapy relieves symptoms - not underlying mitral pathology Surgical treatment for MR: MVR MV repair (MVRe) superior long-term outcomes

INTRODUCTION Transcatheter MV therapies - slower development path -complex anatomy of MV and mitral apparatus minimally invasive approaches – for elderly, severe LV dysfunction and significant comorbidities

CLASSIFICATION Based on functional anatomy groups devices into those targeting : leaflets (percutaneous leaflet plication, percutaneous leaflet coaptation, percutaneous leaflet ablation) annulus (indirect: coronary sinus approach or an asymmetrical approach; direct: true percutaneous or a hybrid approach) chordae (percutaneous chordal implantation) LV (percutaneous LV remodeling)

Circ Cardiovasc Intervent. 2009;2:140-146.)

Leaflet Repair - EDGE-TO-EDGE TECHNIQUE 1991- Alfieri et al - suturing leaflets together to reduce MR in degenerative MR (edge-to-edge leaflet repair) Suturing anterior and posterior mitral leaflet edges near their midpoints double-orifice valve

mmcts.2009.004002

key exclusion criteria – Recent myocardial infarction – Any interventional or surgical procedure within 30 days of the index procedure – Mitral valve orifice area <4 cm2 – Renal insufficiency, endocarditis, rheumatic heart disease mmcts.2009.004002

mmcts.2009.004002

The MitraClip device - 4-mm-wide cobalt -chromium implant with two arms that are opened and closed with the use of the delivery-system handle. The steerable guide catheter and clip delivery system (CDS) are advanced inside the 14 F – 16 F guide catheter. Once the CDS is axially aligned perpendicularly above the line of coaptation of the mitral valve, the clip is opened to 180, the grippers are elevated and the CDS is oriented perpendicular to the free edge of the leaflets.

Data: –EVEREST I: Feasibility study (n=55) –EVEREST II: Randomized trial (n=279) –REALISM: Registry –ACCESS Europe: Registry –TRAMI: Registry –GRASP: Registry –COAPT: Ongoing randomized study to study safety and efficacy –RESHAPE-HF: Randomized study, clip vs. medical therapy

EVEREST I Endovascular Valve Edge to edge REpair pair STudy

EVEREST II Study Design Prospective, randomized, multicenter study Control: surgical mitral valve repair/ replacement Patients randomized 2:1 37 centers in US and Canada Primary Effectiveness Endpoint Freedom from surgery, death, and moderate to severe (3+) or severe (4+) mitral regurgitation at 12 months. Primary Safety Endpoint Freedom from MAE at one month

OUTCOMES Randomly assigned 279 patients in a 2-to-1 ratio to undergo either percutaneous repair (184 patients) or mitral-valve surgery (95 patients) of mitral regurgitation N Engl J Med 2011;364:1395-406

Conclusions from EVEREST II 4 Year Follow up At 4 years - surgery remains the standard of care for treatment of MR among eligible patients. Percutaneous repair -similar mortality and symptomatic improvement but higher rate of MR requiring repeat procedures percutaneous repair - higher rate of residual MR at 1 year- no difference in later occurrence of MR or mitral valve intervention between 1-year and 4-year follow up

TRAMI (Transcatheter Mitral Valve Interventions) register - The German mitral register Established in 2010 in order to assess the safety and efficacy of percutaneous mitral valve therapy in Germany The TRAMI registry is the largest real world cohort of patients treated with MitraClip Mitral Clip was found to be safe and established risk factors for conventional cardiac mitral valve surgery, such as advanced age (≥76 years), female gender, severely reduced LV-EF (<30%) and high logistic EuroScore(≥20%) were not predictive for mortality or major complication rates.

For whom is Mitra Clip Therapy? Mitra clip can be considered as a new treatment option in the following cases: Patients with primaryMR, severe LV dysfunction(LV-EF<30%) and relevant co-morbidities. Symptomatic patients with severe secondaryMR, severe LV dysfunction(EF<30%) and no option for revascularization. Symptomatic patients with severe secondaryMR with mild to moderate LV dysfunction (EF>30%), no option for revascularization and relevant co-morbidities. high operative risk or are inoperable. safe treatment option with low 30 day mortality

INDIRECT ANNULOPLASTY CS Approach (CS Reshaping)

A device placed in the coronary sinus to create tension that is transmitted to annulus. Thus, the annular circumference is decreased and mitral leaflet coaptation improves.

Carillon mitral contour system

Carillon Device Patient Selection Moderate to severe FMR due to ischemic or non ischemic cardiomyopathy. NYHA class II-IV LV EF <40% Dilated mitral annulus/insufficient coaptation length. CRT candidates prior to CRT implant. Stable heart failure medication for 3 months Exclusion Criteria: Primary mitral regurgitation. Coronary artery disease requiring revascularization. Presence of coronary sinus lead Significant renal insufficiency (serum creatinine >2.2 mg/dl

Conclusions of AMADEUS Trial Percutaneous placement of a mitral annuloplasty device based in the coronary sinus (CARILLON Mitral Contour System) has the potential to safely and significantly treat FMR in patients with heart failure with resultant symptomatic benefit

Circulation. 2009;120:326-333

Conclusions of TITAN Trial This study demonstrates that percutaneous CS-based mitral annuloplasty can significantly and safely reduce functional MR severity in HF patients There is significant LV reverse remodelling over 12 months and improved measures of clinical outcome over 24 months

The Viacor PTMA system uses 2 primary structural elements: a multilumen PTFE (Teflon) PTMA catheter and Nitinol (nickeltitanium alloy) PTMA treatment rods. The Viacor 7F, 3-lumen PTMA diagnostic multilumen catheter was advanced over a 0.035-in guide wire through the CSG sheath and into the coronary sinus under fluoroscopic guidance.

Circ Cardiovasc Interv 2009;2;277-284

EVOLUTION Phase I Study J Am Coll Cardiol Intv 2011;4:115–22

J Am Coll Cardiol Intv 2011;4:115–22

EVOLUTION I, EVOLUTION II Suspended Device Name Company Name Trial Technique Current status Carillon Mitral Contour Cardiac Dimensions, Inc. AMADEUS, TITAN, INTEGRAL, TITAN II Indirect annuloplasty Ongoing, CE Monarc Edwards Lifesciences EVOLUTION I, EVOLUTION II Suspended Viacor PTMA Viacor, Inc. PTOLEMY, PTOLEMY II Mitral Cerclage Annuloplasty National Institutes of Health Animal study Animal model

Direct Annuloplasty

Percutaneous energy-mediated cinching approach to direct annuloplasty have included the following: QuantumCor device ReCor device –: high intensity focused ultrasound circumferentially

Catheterization and Cardiovascular Interventions Volume 74, Issue 1, pages 43–48, 1 July 2009

Annuloplasty—Direct: Percutaneous Mechanical Cinching Approach

The Mitralign Percutaneous Annuloplasty System consists of the following devices: Deflectable guide catheter Crossing wire “Bident” translational catheter Pledget Delivery Catheter Plication Lock Delivery Catheter

Pledgets are pulled together (plicated) and locked Femoral access (14 Fr.) approaching the posterior mitral annulus via the left ventricle 2 pairs of surgical pledgets are delivered to the posterior mitral annulus in the area of P1 and P3 Pledgets are pulled together (plicated) and locked Potential to Customize Therapy: Option to implant 1, 2 or 3 pairs of pledgets Adjust the amount of plication to match the heart size or extent of mitral regurgitation Target the location of the implant to match the MR jet

Annuloplasty—Direct: Hybrid Approach

Ventricular remodeling

reduce ventricular dilation by directly remodelingthe LV while also compressing the mitral annular septal-lateral dimension Through a pericardial subxiphoid approach,2 epicardial pads connected by a flexible suture like cord placed on the LV surface The cord is passed through the LV between the 2 papillary muscles, bisecting the ventricle. Shortening of the cord reduces LV size in an anteroposterior dimension

Euro Intervention Supplements (2006) 1 (Supplement A)

Euro Intervention Supplements (2006) 1 (Supplement A)

RESTOR-MV TRIAL significant sustained reductions in LV chamber dimensions and volume Reduced MR and improved survival- compared with mitral annuloplasty

Chordal repair

MitraFlex™ MitraFlex™ is a mitral valve repair system designed for direct thorascopic approach through the apex of a beating heart. The MitraFlex™ system performs the following functions on a beating heart: Stabilization and centering of the mitral valve leaflets Automatic capturing and connection of the approximate midpoint of the leaflets Implantation of an artificial cordae tendonae that controls the movement of the valve leaflets and reduces the annulus thereby reducing or eliminating mitral valve regurgitation

Transcatheter Chordal Implants The MitraFlex device sheath (TransCardiac Therapeutics, Atlanta, Georgia) (top left), clip for leaflet plication (top middle), and artificial chord implantation (top right); the NeoChord device (Neochord, Inc., Minnetonka, Minnesota) implanted from a transapical approach (middle); the Babic device (bottom).

Percutaneous MV Replacement early stages Replacement devices for direct left atrial, antegrade, transseptal and apical delivery being tested in bench and pre-clinical models small number of patients

CURRENT GUIDELINES Nishimura, RA et al. 2014 AHA/ACC Valvular Heart Disease Guideline

who fulfil the echo criteria of eligibility The percutaneous mitral clip procedure may be considered in patients with symptomatic severe secondary MR despite optimal medical therapy (including CRT if indicated) who fulfil the echo criteria of eligibility are judged inoperable or at high surgical risk by a team of cardiologists and cardiac surgeons and who have a life expectancy greater than 1 year (recommendation class IIb,level of evidence C). ESC 2012

CONCLUSION The different percutaneous methods are in their different phases of evolution with few already out of race due to unacceptable practical problems. As the experience will grow, there will be improvement in both the design of the devices and the competence of the operators. different techniques have to be used in combination to offer an effective and long lasting solution.

THANK YOU